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Summary
 
A new surface protein, named NspA, which is distinct from the previously described
 
 Neisseria
meningitidis 
 
outer membrane proteins was identified. An NspA-specific mAb, named Me-1, re-
acted with 99% of the meningococcal strains tested indicating that the epitope recognized by
this particular mAb is widely distributed and highly conserved. Western immunoblotting ex-
periments indicated that mAb Me-1 is directed against a protein band with an approximate
molecular mass of 22,000, but also recognized a minor protein band with an approximate mo-
lecular mass of 18,000. This mAb exhibited bactericidal activity against four meningococcal
strains, two isolates of serogroup B, and one isolate from each serogroup A and C, and passively
protected mice against an experimental infection. To further characterize the NspA protein and
to evaluate the protective potential of recombinant NspA protein, the 
 
nspA 
 
gene was identified
and cloned into a low copy expression vector. Nucleotide sequencing of the meningococcal
insert revealed an ORF of 525 nucleotides coding for a polypeptide of 174 amino acid residues,
with a predicted molecular weight of 18,404 and a isoelectric point of 9.93. Three injections of
either 10 or 20 
 
m
 
g of the affinity-purified recombinant NspA protein efficiently protected 80%
of the mice against a meningococcal deadly challenge comparatively to the 20% observed in
the control groups. The fact that the NspA protein can elicit the production of bactericidal and
protective antibodies emphasize its potential as a vaccine candidate.
 
N
 
eisseria meningitidis
 
 causes both endemic and epidemic
diseases, principally meningitidis and meningococce-
mia (1, 2). This pathogenic bacteria primarily affects young
children between 6 mo and 2 yr of age, but often infects
teenagers (1). The incidence per year of meningococcal
diseases during endemic periods is normally 
 
z
 
1–3 cases per
100,000 in developed countries, but it can be as high as 500
per 100,000 during epidemics (2, 3).
 
N. meningitidis
 
 is classified into 12 serogroups based on
the immunological characteristics of the capsular polysac-
charides found at their surface. Within serogroups, different
serotypes, subtypes, and immunotypes can be identified
based on the antigenic specificity of the major outer mem-
brane (OM)
 
1 
 
proteins and LPS (4). Approximately 90% of
all meningococcal diseases worldwide are caused by isolates
of serogroups A, B, and C (5). Vaccines based on the cap-
sular polysaccharides of serogroups A, C, W-135, and Y
were developed and proved efficient to control outbreaks
and epidemics of meningococcal diseases (6). However,
these vaccines are poorly immunogenic in very young chil-
dren. Moreover, they do not induce immunological mem-
ory and the duration of the protection they provide is rela-
tively short (5, 7–11). Recently, it was demonstrated that
conjugation of capsular polysaccharides of serogroups A
and C to carrier proteins resulted in a better immunogenic-
ity and a longer persistence of specific antibodies against
isolates of these serogroups (12–16). Attempts to develop
an efficient vaccine against serogroup B isolates, which are
responsible for 50–70% of the meningococcal disease in the
developed countries were unsuccessful because the group B
capsular polysaccharide is not a good immunogen in hu-
man, inducing only a poor IgM response of low specificity
which is not protective (17–19). Furthermore, the presence
of closely similar, cross-reactive structures in the glycopro-
teins of neonatal human brain tissue might discourage attempts
to improve the immunogenicity of serogroup B polysaccha-
ride (10).
To develop a vaccine effective against meningococci of
serogroup B several non-capsular surface structures are un-
der investigation (6, 10). Importantly, the presence of bac-
tericidal antibodies against 
 
N. meningitidis 
 
have been strongly
correlated with human immunity and protection (20–22).
For that reason, it is believed that non-capsular surface anti-
gens shown to stimulate bactericidal antibodies should be
considered as the prime vaccines candidates (6). Early stud-
 
1
 
Abbreviations used in this paper:
 
 pI, isoelectric point; OM, major outer
membrane; Opa, opacity protein; PVDF, polyvinylidene difluoride.
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ies using sera of immunized volunteers and convalescent
patients indicated that certain meningococcal surface pro-
teins such as the ones responsible for serotype specificity
and LPS could induce bactericidal antibodies and be in-
volved in protection (23, 24). mAbs were then used to
clearly establish the protective potential of certain menin-
gococcal major surface proteins such as the PorA (class 1),
PorB (class 2/3), and Opc (class 5C) (25–28).
Different vaccines based on OM proteins were recently
evaluated in clinical trials and efficiency between 50 and 80%
were recorded (6, 10). These first generation OM proteins
vaccines often induced protection against a limited number
of strains. Thus, these vaccines could be used during men-
ingococcal epidemics when the antigenic variation of the
meningococci causing diseases is relatively low. The speci-
ficity of the bactericidal antibodies induced by these vac-
cines was determined to be directed mainly against PorA
and Opc proteins (29, 30). However, the PorA-specific
bactericidal antibodies were found to be directed against
epitopes located in surface-exposed highly variable regions
(31). Moreover, the Opc protein was shown to be pro-
duced by only 60% of strains of different serogroups (32),
and by 
 
z
 
20% of serogroup B isolates (33). To improve the
protection conferred by the PorA protein, strategies such as
multivalent PorA vaccines or the incorporation of addi-
tional epitopes on PorA protein are presently under study
(34–36). Proteins induced by iron limitation such as FrpB
and Tbp-2 are also likely vaccine candidates, but they also
show type specificity with respect to the induction of bac-
tericidal antibodies (37–40). Antigenically conserved pro-
teins such as the Lip (or H.8) (41, 42) and the Rmp (or
class 4) (43) proteins were identified in the meningococcal
OM, but antibodies directed against these proteins were
found to be nonbactericidal. Moreover, high concentra-
tions of antibodies to the Rmp protein were also reported
to block the bactericidal activity of antibodies directed
against PorA protein and could prevent the efficient killing
of meningococcal cells (43).
In the present report, we described a new highly con-
served protein, called NspA for Neisserial surface protein
A, which was shown to be present in the OM of all 
 
N.
meningitidis
 
 strains tested. An mAb, named Me-1, which is
directed against the NspA protein was found to be bacteri-
cidal and to passively protect BALB/c mice against experi-
mental infections. To further characterize this protein and
to clearly establish its protective potential, the 
 
nsp
 
A gene
was identified, sequenced and cloned into a low copy ex-
pression vector to obtain large quantities of the recombi-
nant protein. In addition, we present data that demonstrate
that the injection of purified recombinant NspA protein ef-
ficiently protect BALB/c mice against a bacterial challenge
with a lethal dose of a meningococcal strain of serogroup B.
 
Materials and Methods
 
Bacterial Strains and Plasmids.
 
A collection of 250 
 
N. meningi-
tidis
 
 strains was used in this study. The panel of strains included 22
isolates of serogroup A, 44 isolates of serogroup B, 56 isolates of
serogroup C, 1 isolate of serogroup 29-E, 7 isolates of serogroup
W-135, 1 isolate of serogroup X, 3 isolates of serogroup Y, 2 iso-
lates of serogroup Z, and 114 isolates that were not serogrouped.
The following 
 
Neisseria
 
 species were also tested: 43 
 
N. gonorrhoeae
 
,
4 
 
N. cinerea
 
, 7 
 
N. lactamica
 
, 1 
 
N. flava,
 
 1 
 
N. flavescens
 
, 3 
 
N. mucosa
 
,
4 
 
N. perflava/sicca
 
, 4 
 
N. perflava
 
, 1 
 
N. sicca
 
, 1 
 
N. subflava
 
 and 5 
 
Mo-
raxella catarrhalis
 
. The 
 
Neisseria
 
 strains were grown overnight on
chocolate agar plates at 37
 
8
 
C in an atmosphere containing 5%
CO
 
2
 
. Cultures were stored at 
 
2
 
70
 
8
 
C in heart infusion broth
(Difco Laboratories, Detroit, MI) with 20% (vol/vol) glycerol
(Sigma Chemical Co., St. Louis, MO). These isolates were ob-
tained from the Caribbean Epidemiology Centre (Port of Spain,
Trinidad); Children’s Hospital of Eastern Ontario (Ottawa, Canada);
Department of Saskatchewan Health (Regina, Canada), Laboratoire
de Santé Publique du Québec (Montréal, Canada); Max-Planck
Institut fur Molekulare Genetik (Berlin, Germany); Montreal
Children Hospital (Montreal, Canada), Victoria General Hospital
(Halifax, Canada), Laboratory Centre for Disease Control (Ottawa,
Ontario), and our own strains collection.
The following control bacterial species were also used: 
 
Alcali-
genes feacalis
 
 (ATCC 8750; American Type Culture Collection,
Rockville, MD), 
 
Bordetella pertussis
 
 9340, 
 
Citrobacter freundii
 
(ATCC 2080), 
 
Edwarsiella tarda 
 
(ATCC 15947), 
 
Enterobacter cloaca
 
(ATCC 23355), 
 
Enterobacter aerogenes
 
 (ATCC 13048), 
 
Flavobacte-
rium odoratum
 
 (LSPQ2135), 
 
Haemophilus influenzae
 
 type b (Eagan
strain), 
 
Klebsiella pneumoniae
 
 (ATCC 13883), 
 
Proteus rettgeri
 
 (ATCC
25932), 
 
Proteus vulgaris
 
 (ATCC 13315), 
 
Pseudomonas aeruginosa
 
(ATCC 9027), 
 
Salmonella typhimurium
 
 (ATCC 14028), 
 
Serratia marce-
scens
 
 (ATCC 8100), 
 
Shigella flexneri
 
 (ATCC 12022), 
 
Shigella sonnei
 
(ATCC 9290) and 
 
Streptococcus pnenumoniae
 
 WU2.
 
Escherichia coli
 
 JM109 (
 
end
 
A1 
 
rec
 
A1 
 
syr
 
A96 
 
thi
 
-1 
 
hsd
 
R17(rk
 
2
 
 mk
 
1
 
)
 
rel
 
A1 
 
sup
 
E44 
 
l
 
2
 
 
 
D
 
(
 
lac
 
-
 
pro
 
AB) [F’
 
tra
 
D36 
 
pro
 
AB 
 
lac
 
I
 
q
 
Z
 
D
 
M15]) (44),
LE392 (F
 
2
 
 
 
hsd
 
RS514(rk
 
2
 
,mk
 
2
 
) 
 
sup
 
E44 
 
sup
 
F58 
 
lac
 
Y1 or 
 
D
 
(
 
lac
 
IZY)6
 
gal
 
K2 
 
gal
 
T22 
 
met
 
B1 
 
trp
 
R55 
 
l
 
2
 
) (45), and BL21(DE3) (F
 
2
 
 
 
dcm
omp
 
T 
 
hsd
 
S(r
 
B
 
2
 
 mb
 
B
 
2
 
) 
 
gal 
 
l
 
(DE3) (46) were grown on LB agar or
broth (GIBCO BRL, Gaithersburg, MD) at 37
 
8
 
C. Where appro-
priate 
 
E. coli
 
 strains or transformants were grown on media con-
taining 25 
 
m
 
g of ampicillin (Sigma) per ml. The low copy plasmid
pWKS30, which carries a gene for resistance to ampicillin, a mul-
tiple cloning region flanked by the T7 and T3 RNA polymerase
promoters, the 
 
lac
 
Z
 
a
 
 gene, and the bacteriophage f1 origin of
replication for production of single stranded DNA was described
in details elsewhere (47).
 
Antigen Preparation.
 
Lithium chloride extractions of OM prepa-
rations from one 
 
N. gonorrhoeae 
 
strain A1 and nine meningococcal
strains two of serogroup A (604A and Z4063), one of serogroup
B (608B [B:2a:P1.2:L3]), two of serogroup C (2241C and 59C),
one of serogroup 29-E, one of serogroup W-135, one of sero-
group Y (SLATY) and one of serogroup Z (SLATZ) were per-
formed as described by Brodeur et al. (28). Protein concentrations
were determined by the Lowry method adapted to membrane
fractions (48).
 
Generation of mAb Me-1.
 
Mice were injected intraperitoneally
with 20 
 
m
 
g of OM preparation extracted from the meningococ-
cal strain 604A mixed with Freund’s complete adjuvant (GIBCO
BRL), and then 3 wk later were injected with 20 
 
m
 
g of OM prepa-
ration  extracted from the meningococcal strain 2241C mixed
with Freund’s incomplete adjuvant. 3 d before the fusion proce-
dure, the selected mouse received a final intravenous injection of
10 
 
m
 
g of OM preparation extracted from the meningococcal
strain 2241C. The fusion protocol used to produce the hybrid-
oma cell lines was described previously by Hamel et al. (49). Hy-
brid clone supernatants were tested for specific antibody produc- 
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tion by ELISA, as previously described (49), using meningococcal
OM preparations as coating antigens (7.5 
 
m
 
g of protein per ml).
Specific hybrids were cloned by sequential limiting dilutions, ex-
panded, and frozen in liquid nitrogen. The class, subclass and
light-chain type of the mAb were determined by ELISA with
commercially available reagents (Southern Biotechnology Associ-
ates Inc., Birmingham, AL). A dot enzyme immunoassay was used
for the rapid screening of the mAb against the bacterial strains as
described elsewhere (50).
 
SDS-PAGE, Western Immunoblotting, Plaque, and Colony Blot
Assays.
 
Meningococcal OM preparations were resolved by elec-
trophoresis by using the discontinuous buffer system of Laemmli (51)
with 14% (wt/vol) gels, and Western blot analyses were per-
formed as described previously with the following modifications
(52). The proteins were transferred from the gels to the nitrocel-
lulose membranes using a semi-dry apparatus (Bio-Rad Labs.,
Hercules, CA). A current of 60 mA per gel was applied for 20
min in the electroblot buffer consisting of 25 mM Tris-HCl, 192
mM glycine, and 20% (vol/vol) methanol, pH 8.3. The presence
of LOS in the different antigen preparations was visualized by sil-
ver staining as described by Tsai and Frasch (53). Recombinant
plaques were blotted onto nitrocellulose membranes using the fol-
lowing protocol. The plates were incubated 15 min at 
 
2
 
20
 
8
 
C to
harden the top agar, and nitrocellulose membranes were gently
applied onto the surface of the plates for 30 min at 4
 
8
 
C to absorb
the proteins produced by the recombinant viral clones. The
membranes were then washed in PBS Tween 0.02% (vol/vol).
The plaque blots were sequentially incubated with tissue culture
supernatant of mAb Me-1, peroxidase-labeled goat anti–mouse
immunoglobulin (Jackson ImmunoResearch Laboratories Inc.,
West Grove, PA) and the 
 
o
 
-dianisidine (Sigma) peroxidase sub-
strate as described previously (52). Colony blots of 
 
E. coli
 
 transfor-
mants were performed as described by (45).
 
Cloning the Gene for the NspA Protein. A  lGEM-11 genomic
DNA library from N. meningitidis strain 608B was constructed ac-
cording to the manufacturer’s recommendations (Promega, Mad-
ison, WI). The recombinant phages were used to infect E. coli
strain LE392 which was then plated onto LB agar. The plaques
were screened with mAb Me-1 and the reactive clones were
plaque purified twice. The phage DNA from one positive clone
was extracted and purified from 10 ml of phage lysate using the
LambdaSorb Phage Adsorbent following the manufacturer’s rec-
ommendations (Promega). The DNA was then digested with
SacI, and the fragments were purified by phenol extraction from
low melting agarose gels, and ligated into the SacI-digested plas-
mid pWKS30 and transformed into E. coli strain JM109 by elec-
troporation according to the manufacturer’s recommendations
(Bio-Rad). To further reduce the size of the insert, the SacI frag-
ment was digested with ClaI, and the fragments were purified by
agarose gel electrophoresis and ligated into the ClaI-digested plas-
mid pWKS30 and the recombinant plasmid was used to transform
E. coli strain JM109 by electroporation. The transformants were
screened with mAb Me-1, and two plasmids recovered from two
reactive clones were designated pN2202 and pN2203.
DNA Sequencing. The Double Stranded Nested Deletion Kit
from Pharmacia Biotech Inc. (Piscataway, NJ) was used according
to the manufacturer’s instructions to generate a series of nested
deletions from the recombinant plasmids pN2202 and pN2203.
The resulting truncated inserts were sequenced from the M13
forward primer with the Taq Dye Deoxy terminator Cycle Se-
quencing Kit using an Applied Biosystems Inc. (Foster City, CA)
automated sequencer model 373A according to the manufac-
turer’s recommendations. Both strands of the insert were se-
quenced. Alignment of the sequences was accomplished by using
Geneworks Software (Intelligenetics, Inc., Mountain View, CA).
Sequence homology searches in GenBank and Swissprot data-
bases were accomplished using the Geneworks, BLAST, BLIZT,
and FASTA software.
NH2-terminal Amino Acid Sequence Analysis of the Native Menin-
gococcal NspA Protein. The protein present in the OM of N. menin-
gitidis strain 608B were resolved by SDS-PAGE and then trans-
ferred to polyvinylidene difluoride (PVDF) membrane (Bio-Rad)
by the method of Matsudaira (54). The PVDF membrane was
stained with Coomassie Blue, the NspA band was excised, and then
the NH2-terminal amino acid sequence was analyzed with an au-
tomated protein sequencer by the Service de Séquence des Protéines
de l’Est du Québec (Centre de Recherche du CHUL, Québec,
Canada).
Production and Purification of the Recombinant NspA Protein. The
recombinant NspA protein was purified from the culture super-
natant by affinity chromatography. To generate the affinity chro-
matography media, mAb Me-1 was first purified from ascitic fluid
using protein A–Sepharose CL-4B (Pharmacia) and was then im-
mobilized on CNBr-activated Sepharose 4B (Pharmacia) accord-
ing to the manufacturer’s instructions. To obtain the NspA re-
combinant protein, the plasmid pN2202 was used to transform E.
coli strain BL21(DE3) by electroporation. An overnight culture of
the transformed E. coli strain BL21(DE3) was inoculated in LB
broth containing 25 mg/ml of ampicillin and was incubated 4–5 h
at 378C with agitation. No induction step was used since the ex-
pression of the NspA protein was under the control of the gene’s
own promoter. The bacterial cells were removed from the cul-
ture media by centrifugation at 12,000 g for 30 min at 48C. The
supernatant was filtered onto a 0.22-mm membrane and concen-
trated using an ultrafiltration apparatus (Amicon Inc., Beverly,
MA) and a membrane with a molecular cut off of 10,000. To sol-
ubilize the membrane vesicles, Empigen BB (Calbiochem Nova-
biochem, La Jolla, CA) was added to the concentrated culture su-
pernatant to a final concentration of 1% (vol/vol), incubated at
room temperature for one h, and then dialyzed overnight against
10 mM Tris-HCl buffer, pH 7.3, containing 0.05% Empigen
(vol/vol). The antigen preparation was added to the affinity gel
and incubated overnight at 48C with constant agitation. The gel
was poured into a chromatography column and washed exten-
sively with of 10 mM Tris-HCl buffer, pH 7.3, containing 0.05%
Empigen (vol/vol). The NspA protein was eluted from the col-
umn with 1 M LiCl in Tris-HCl buffer, pH 7.3. The fractions
containing the NspA protein were pooled and dialyzed exten-
sively against 10 mM Tris-HCl buffer, pH 7.3, containing 0.05%
Empigen (vol/vol).
Bactericidal Assay. The bactericidal activity of purified mAb
Me-1 was tested in vitro as described previously (55) with the fol-
lowing modifications. 10 ml of a meningococcal suspension ad-
justed to 3 3 105 CFU/ml was dispensed into the wells of sterile
flat-bottom 96-well plates (GIBCO BRL) containing 70 ml of
PBS with 0.15 mM CaCl2, 0.5 mM MgCl2, and 0.1% BSA, 10 ml
of guinea pig serum as a source of complement, and 10 ml of dif-
ferent dilution of protein A purified mAb Me-1, or heat-inacti-
vated mouse serum. Duplicate antigen/antibody mixtures were
incubated either in the absence of complement or with heat-inac-
tivated guinea pig serum. After incubation for 1 h at 378C, 10 ml
of each mixture were plated onto chocolate agar plates. The plates
were incubated overnight at 378C, after which time the bacterial
colonies were counted.
Protection Experiments. The mouse model of infection used
for the passive and active protection experiments was described1176 Conserved Meningococcal Protein Confers Protection
previously (28). In brief, the N. meningitidis strain 608B (B: 2a:
P1.2:L3) was passaged twice in mice before the bacterial chal-
lenge. For inoculation of mice, meningococci were removed
from the chocolate agar plates after z20 h of incubation and sus-
pended in PBS. The bacterial suspension was adjusted to an opti-
cal density of 0.25 (l 5 490 nm) and diluted to obtain 1,000
CFU per ml in brain heart infusion broth (Difco) containing 4%
mucin (from porcine stomach type II; Sigma) and 1.5% hemoglo-
bin (Oxoid Ltd., Nepean, Canada). All inocula were verified by
colony counts. The number of surviving mice were recorded 24
and 72 h after the bacterial challenge. The mice that survived a
bacterial challenge were always monitored for an additional 2 wk
to see if there was any sign of infection. To evaluate the protec-
tive potential of mAb Me-1, 600 ml of ascitic fluid per mouse was
injected intraperitoneally 18 h before the challenge. The mice in
the control groups received the same volume of ascitic fluid con-
taining an unrelated mAb or PBS. For the active protection ex-
periments, groups of mice were injected three times at 3-wk in-
tervals with 10 or 20 mg of affinity-purified NspA recombinant
protein and 25 mg of QuilA (CedarLane Laboratories, Hornby,
Ontario, Canada) as the adjuvant. Control mice were injected
with either 20 mg of BSA (Sigma), concentrated E. coli BL21(DE3)
supernatant, or PBS. 2 wk after the third injection the mice were
used for the protection experiments. Blood samples were col-
lected via the periorbital sinus before each immunization and 10 d
after the third injection for mice receiving 20 mg of purified
NspA protein or E. coli concentrated supernatant. The specific ti-
ter of each of these sera was determined by ELISA against menin-
gococcal OM preparation extracted from the meningococcal
strain 608B. The serum dilution for which an absorbance reading
of 0.1 (l 5 410/630 nm) was recorded after background subtrac-
tion was considered to be the titer of this serum. The bactericidal
activity of these sera was evaluated as described previously and the
serum dilution giving 50% killing of meningococci was consid-
ered to be the bactericidal titer.
Results
Identification of the Meningococcal NspA Protein. Mice were
immunized  with different combinations of meningococcal
OM preparations in order to obtain hybridoma clones se-
creting mAbs specific for highly conserved surface antigens.
mAb Me-1 was derived from one of these fusion experi-
ments. The mouse that was used for that particular fusion
was successively immunized with OM preparations ob-
tained from one serogroup A strain (604A) and one sero-
group C strain (2241C). mAb Me-1 was selected because it
reacted with all nine meningococcal OM preparations
tested, but did not recognize the OM preparation extracted
from N. gonorrhoeae strain A1. The hybridoma cell line se-
creting mAb Me-1 was subcloned twice by limiting dilu-
tion. The class, subclass, and light chain specificity of this
mAb were determined to be IgG2ak. A dot enzyme assay
using whole cell preparations as the source of antigen was
used to evaluate the specificity and the antigenic conserva-
tion of the epitope recognized by mAb Me-1. mAb Me-1
reacted with 248 out of the 250 meningococcal strains
tested (99.2%). The panel of strains used for the dot assay is
described in detail in Materials and Methods. Only one
non-typable meningococcal strain and one serogroup B
strain were not recognized by the mAb. This result clearly
indicates that the epitope recognized by this particular mAb
is widely distributed among meningococcal strains. It also
suggests that the particular epitope recognized by mAb Me-1
is not restricted to serologically related isolates since the
panel of meningococcal strains were chosen to represent
the major disease causing groups of strains. Moreover, two
other NspA-specific mAbs, called Me-2 and Me-7, which
were generated from other fusion experiments, reacted
with the two meningococcal strains that were not recog-
nized by mAb Me-1 (56). This latter result indicates that
the epitopes recognized by these NspA-specific mAbs are
present in the OM of all meningococcal strains tested so
far. The reactivity of the mAb Me-1 was also evaluated
with other Neisseria species. Out of the 74 non-meningo-
coccal strains tested, mAb Me-1 reacted only with one N.
lactamica strain, but not with any other Neisseria species
tested. This mAb did not recognize any other gram-nega-
tive and gram-positive bacterial strains tested.
Western immunoblotting experiments indicated that
mAb Me-1 reacted with a protein band with apparent mo-
lecular mass of 22,000 (Fig. 1 B). This mAb also reacted
with a minor protein band with apparent molecular mass of
18,000. To observe the minor band, the total protein con-
centration of 5 mg that is normally applied to each well had
to be increased to 7.5 or 10 mg. Analysis of SDS-PAGE and
their corresponding Western immunoblots indicated that
despite the variation normally observed in the OM protein
migration profiles, the molecular mass of the 22,000 pro-
tein band is constant among meningococcal isolates. How-
ever, the amount of 22-kD protein band present in the dif-
ferent OM preparations varied from one meningococcal strain
to another.
Cloning of the nspA Gene. A meningococcal chromosomal
library was constructed from N. meningitidis strain 608B in
LambdaGEM-11. The genomic DNA was partially di-
gested with Sau3AI and fragments ranging between 9 and
23 kb were purified and ligated to the BamHI sites of the
LambdaGEM-11 bacteriophage arms. 19 positive plaques
were identified after the immunoscreening of the library
Figure 1. Coomassie blue-
stained 14% SDS-PAGE gel (A)
and Western immunoblots (B)
showing the reactivity of mAb
Me-1 with different meningococ-
cal OM preparations (7.5 mg/lane):
serogroup A strain Z4063 (lane 2);
serogroup B strain 608B (lane
3); serogroup C strain 59 (lane 4);
serogroup W-135 strain (lane 5);
and serogroup Y strain SLATY
(lane  6). The arrow indicates the
location of the 22-kD NspA pro-
tein band. On the left, mol wt
standard proteins are phosphory-
lase b (97,400), BSA (66,200),
ovalbumin (45,000), carbonic an-
hydrase (31,000), soybean trypsin
inhibitor (21,500), and lysozyme
(14,400).1177 Martin et al.
with mAb Me-1. After amplification and DNA purifica-
tion, one viral clone which had a 13-kb insert was selected
for the subcloning experiments. After digestion of this
clone with SacI, two fragments of 5 and 8 kb were ob-
tained, purified, and ligated into the SacI restriction site of
the plasmid pWKS30. E. coli strain JM109 transformed
with the recombinant plasmids were screened with mAb
Me-1. Positive colonies were observed only when the bac-
teria were transformed with the plasmid carrying the 8-kb
insert. Western blot analysis of the positive clones showed
that the protein expressed by E. coli strain JM109 was com-
plete and migrated on SDS-PAGE gel like the N. meningi-
tidis NspA protein. A purified 8-kb fragment obtained from
a positive clone was digested with ClaI to further reduce
the size of the insert. The resulting 2.75-kb fragment was
then ligated into the ClaI site of the pWKS30 plasmid.
Western blot analysis of the resulting clones clearly indi-
cated once again that the protein expressed by E. coli strain
JM109 was complete and migrated on SDS-PAGE gel like
the native N. meningitidis NspA protein (Fig. 2, B and C,
lane 2). Both the 22,000 and the minor 18,000-protein
band were produced by recombinant E. coli cells and were
recognized by mAb Me-1. Restriction analysis indicated
that two clones, designated pNP2202 and pNP2203, car-
ried the 2.75-kb insert in opposite orientations.
Sequence Analysis of nspA. The two plasmids pN2202
and pN2203 were selected to proceed with the sequencing
of the nspA gene. Both expressed the NspA protein, indi-
cating that the gene is being transcribed from a promoter
located on the DNA insert. Nested sets of deletions were
made for both clones by ExoIII digestion. The resulting
truncated inserts were then sequenced from the M13 for-
ward primer present on the plasmid pWKS30. The DNA
sequence deduced from the DNA templates of the deletion
subclones was used to design complementary oligonucle-
otide primers to complete the sequencing of the entire
open reading frame (ORF) encoding the nspA gene. Fig. 3
shows the sequence of a portion of the 2.75-kb insert which
contains the nspA gene. This sequence was submitted to
GenBank and assigned the accesssion number U52066.
The sequence analysis revealed an ORF of 525 nucleotides
which start with an ATG codon at nucleotide 143 and ends
with a TGA stop codon at nucleotide 667. A putative ribo-
some binding (AGGA) site was identified eight nucleotides
upstream from the start codon and is boxed in the Fig. 3.
This open reading frame codes for a 174–amino acid resi-
dues polypeptide with a predicted pI of 9.93 and a molecu-
lar mass of 18,404. 
NH2-terminal amino acid analysis of the meningococcal
22-kD protein band present in the OM preparation of
strain 608B indicated that the first 10 amino acid residues
were E-G-A-S-G-F-Y-V-Q-A. Comparison of this se-
quence with the deduced amino sequence obtained after
sequencing the nspA gene indicated the existence of a 19–
amino acid residues leader peptide which is cleaved in the
mature meningococcal protein (underlined in Fig. 3).
Moreover, the NH2-terminal portion of the predicted
polypeptide was found using Kyte-Doolittle analysis (Fig.
4) to be hydrophobic, which is typical of leader peptides of
Figure 2. Silver-stained (A), Coomassie blue-stained (B) 14% SDS-
PAGE gels and corresponding Western immonoblots (C) showing the af-
finity-purified NspA protein that was injected to BALB/c mice used for
the active protection experiments and the reactivity of mAb Me-1 with 5
mg of meningococcal OM preparation extracted from strain 608B (lane
2), 5 mg of OM protein preparation obtained from E. coli strain
BL21(DE3) transformed with plasmid pN2202 (lane 3), concentrated cul-
ture supernatant obtained after 4 h of incubation of E. coli strain
BL21(DE3) transformed with plasmid pN2202 (lane 4) and 2 mg of affin-
ity-purified NspA protein (lane 5). The arrow indicates the location of
the 22-kD NspA protein band. On the left, mol wt standard proteins are
Phosphorylase b (97,400), BSA (66,200), ovalbumin (45,000), carbonic
anhydrase (31,000), soybean trypsin inhibitor (21,500), and lysozyme
(14,400).
Figure 3. Nucleotide and amino acid sequences of the gene encoding
the N. meningitidis strain 608B NspA protein. The open reading frame of
525 bp extends from the start codon at base 143 to the stop codon at base
667. A 19–amino acid leader peptide is underlined, and a putative ribo-
some binding site is boxed. These sequence data are available from Gen-
Bank under accession number U52066. 
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other known membrane proteins (57). The low amount of
18-kD protein band present in the meningococcal OM
preparation after separation on SDS-PAGE prevented the
same analysis. For that reason, affinity-purified recombinant
protein was used to overload a gel in order to obtain
enough of the minor protein band to resolve its NH
 
2
 
-ter-
minal amino acid sequence. The first five amino acid resi-
dues of the minor 18-kD band were determined to be
E-G-A-S-G-F, which corresponded exactly to the first
amino acid residues of the mature meningococcal protein
without its leader peptide. This result and the observed re-
activity of mAb Me-1 with both protein bands suggest that
the 22- and the 18-kD protein bands are related and possi-
bly are the same protein.
No significant homology was found between the de-
duced amino acid sequence of the NspA protein and the
sequences compiled in GenBank and Swissprot databases
indicating that this protein has never been described previ-
ously. These searches indicated the existence of weak ho-
mology of the NspA protein with the 
 
Neisseria 
 
opacity
(Opa) family of protein. Pairwise comparison of the differ-
ent Opa protein sequences with the NspA sequence re-
vealed identities between 20 and 28%. Closer analysis indi-
cated that the observed homology with the Opa proteins
seems to be clustered in two particular regions on the
NspA protein. The first region that showed 62.5% homol-
ogy with some of the Opa proteins is composed of 24
amino acid residues located between position 126 and 149.
The second region which showed 60% homology with the
carboxyl-terminal regions of Opa proteins, is made up of
the last 10 amino acid residues at the carboxyl-terminal of
the NspA protein.
 
Production and Purification of the Recombinant NspA Protein.
 
The purification protocol was based on the observation
that the recombinant NspA protein produced by 
 
E. coli
 
BL21(DE3) strain carrying the plasmid pNP2202 can be
found in large amounts in the OM, but can also be ob-
tained from the culture supernatant in which it is one of
the most abundant proteins (Fig. 2 
 
B
 
). Preliminary experi-
ments indicated that an induction step using isopropyl-
 
b
 
-
 
d
 
-thiogalactopyranoside (IPTG) was not necessary since
it did not significantly increase the level of NspA protein
which was constitutively produced by 
 
E. coli
 
 BL21(DE3)
strain transformed with plasmid pN2202. This result indi-
cated that this neisserial promoter can efficiently control
the expression of the 
 
nsp
 
A gene in 
 
E. coli
 
. Therefore, the
culture supernatant was the material used to purify the re-
combinant NspA protein using affinity chromatography.
Silver-stained gel indicated that the amount of 
 
E. coli
 
 LPS
present after affinity chromatography is greatly reduced
compared to the amount initially present in the concen-
trated supernatant (Fig. 2 
 
A
 
). The recombinant NspA pro-
tein was still recognized by mAb Me-1 after solubilization
and purification (Fig. 2 
 
C
 
). The purity of the NspA protein
used to immunize mice was estimated by SDS-PAGE to be
 
.
 
90%.
 
Determination of the Bactericidal Activity and the Protective
Potential of mAb Me-1.
 
To demonstrate the bactericidal
activity of mAb Me-1 an in vitro assay was performed us-
ing guinea pig serum and protein A–purified mAb. The
bactericidal activity of mAb Me-1 against the meningococ-
cal strain 608B is presented in Fig. 5. 7 
 
m
 
g/ml of purified
mAb Me-1 were required to kill 50% of the meningococ-
cal cells. Higher concentrations of purified mAb resulted in
a sharp decrease in the recorded CFU 
 
<
 
100%. Heat-inacti-
vation for 30 min at 56
 
8
 
C of the guinea pig serum com-
pletely abolished the bactericidal activity of mAb Me-1.
50% of killing were recorded for three other meningococ-
cal strains, one of each serogroup A (strain Z4063), B ([B:
15:P1.7] strain 164), and C (strain 3), when 20 
 
m
 
g/ml of
purified Me-1 was used in the bactericidal assay.
The ability of mAb Me-1 to passively protect mice
against a lethal infection with the meningococcal strain
608B was evaluated and the combined results from three
separate experiments are presented in Table 1. Intraperito-
neal injection of 600 
 
m
 
l of ascitic fluid containing mAb
Me-1 18 h before the bacterial challenge with a 1,000 CFU
increased the survival rate of mice 
 
<
 
76% comparatively to
30% observed in the control groups receiving ascitic fluid
containing either an unrelated mAb or PBS.
 
Immunization of BALB/c Mice with Affinity-purified Recom-
binant NspA Protein and Protection Experiments.
 
Affinity-puri-
Figure 4. Schematic representation of a Kyte-Doolittle hydrophobicity
plot of the N. meningitidis NspA protein.
Figure 5. Bactericidal activity of protein A–purified mAb Me-1 against
N. meningitidis strain 608B. Guinea pig serum (closed circles) or heat inacti-
vated guinea pig serum (open circles) were used as the source of comple-
ment to evaluate the bactericidal activity.
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fied recombinant meningococcal NspA protein was used to
immunize BALB/c mice in order to determine its ability to
induce a protective immune response against challenge
with a lethal dose of N. meningitidis 608B strain (Table 2).
80% of the mice immunized with three injections of either
10 or 20 mg of purified recombinant meningococcal NspA
protein survived the bacterial challenge comparatively to 0
to 20% in the control groups. Survivors at 72 h did not suc-
cumb during an additional two weeks of observation. The
mice in the control group injected with concentrated E.
coli culture supernatant were not protected against the bac-
terial challenge indicating that the components present in
the culture media and other E. coli antigens that might be
present in small amounts after purification do not contrib-
ute to the observed protection against N. meningitidis.
Serum samples were obtained before immunization and
after the third injection but before the bacterial challenge
for mice immunized with 20 mg of affinity-purified protein
or E. coli concentrated supernatant. The titer of these sera
were determined by ELISA using meningococcal OM
preparation as coating antigen. The reciprocal serum titers
varied from 4,800 to 51,200 for the mice injected with 20
mg of protein, but were below 200 for the mice in the con-
trol group. Western immunoblotting experiments con-
firmed that the antibodies present in the sera obtained from
the immunized mice recognized the recombinant protein,
but also reacted with the native meningococcal NspA pro-
tein present in the OM preparation (data not shown). The
reciprocal bactericidal titers of these sera varied from 10 to
90 when tested against the homologous strain 608B. Bacte-
ricidal titers between 10 and 20 were recorded when these
sera were tested against the meningococcal strain 44 (B:4:
P1.12). This latter result indicated that the injection of re-
combinant NspA protein to mice generate cross-reactive
bactericidal antibodies, and correlated well with the ELISA
titers. No bactericidal activity was recorded for the sera ob-
tained from mice in the control group. Analysis of the sera
obtained from the two mice who died following the bacte-
rial challenge revealed that they had the lowest ELISA titers
(4,800) as well as no bactericidal activity.
Discussion
In addition to the well known major OM proteins, it is
believed that other antigenically stable surface proteins
could play an important role in the protection against N.
meningitidis and could become for that reason interesting
vaccine candidates. Already, it was demonstrated that mi-
nor meningococcal antigens such as iron-regulated proteins
could induce bactericidal antibodies that protected mice
against experimental infection (37, 38). We have identified
a minor antigen which is present in the OM of all menin-
gococcal strains tested so far. To our knowledge this pro-
tein, which was called NspA for Neisserial surface protein
A, was not described previously. Interestingly, comparison
of the deduced amino acid sequence obtained after se-
quencing the nspA gene and the protein sequences com-
piled in the available databases revealed that two regions lo-
cated between amino acid residues 126 and 149 and the last
10 residues at the carboxyl end showed z60% homology
with members of the Neisserial opacity protein (Opa) family
of proteins. These Opa proteins appear to be involved in
cells adherence and invasion of epithelial or endothelial hu-
man cells (58). The observed similarity is clustered in two
regions that were described to be highly conserved among
Opa proteins (59, 60). The first conserved region is located
Table 1. Passive Protection of Balb/c Mice Conferred by mAb
Me-1 Against Infection with N. meningitidis Strain 608B
Groups
Number of living mice 
after the bacterial 
challenge*
% of survival
(range)‡ 24 h 72 h
Me-1–injected mice§ 29/30 23/30 76
(60–100)
Control micei 10/30 9/30 30
(0–40)
*The mice were challenged with 1 ml of a suspension containing 1,000
CFU of N. meningitidis strain 608B, 4% mucin (Sigma), and 1.6% he-
moglobin (Oxoid).
‡Combined results of three separate protection experiments. The range
indicates the lowest and highest survival rates obtained.
§600 ml of ascitic fluid containing mAb Me-1 were injected intraperito-
neally 18 h before the bacterial challenge.
iThe mice in the control group received 600 ml of ascitic fluid contain-
ing unrelated mAb or phosphate buffered saline.
Table 2. Immunization of Balb/c Mice with Affinity-purified 
Recombinant NspA Protein Confers Protection against Subsequent 
Challenge with N. meningitidis Strain 608B
Number of living mice 
after the bacterial 
challenge*
Groups 24 h 72 h % Survival
10 mg of purified
NspA protein 20/20 16/20 80
20 mg of purified
NspA protein 9/10 8/10 80
20 mg of BSA 6/10 2/10 20
20 mg of concentrated
E. coli supernatant 7/10 2/10 20
Phosphate buffered
saline 8/10 0/10 0
*The mice were challenged with 1 ml of a suspension containing 1,000
CFU of N. meningitidis strain 608B, 4% mucin (Sigma), and 1.6% he-
moglobin (Oxoid).1180 Conserved Meningococcal Protein Confers Protection
on Opa proteins between two highly variable regions,
named HV1 and HV2, which display considerable hetero-
geneity in sequence and in length, while the second region
is found at the carboxyl end. These results suggest that the
NspA protein could somehow be a smaller homologue of
the Opa proteins and for that reason could be implicated in
the meningococcal pathogenesis. However, beside the ob-
served homology in the conserved regions, the NspA pro-
tein does not share two of the well-known characteristics of
the Opa proteins such as the antigenic variability and the
translational control of their expression during phase varia-
tion by multiple repeats of the nucleotide sequence (CTCTT)
(59, 60). This homology can also be explained by the fact
that the two regions of the NspA protein could be included
in functional domains that are common to several OM
proteins. Indeed, these two regions are hydrophobic as de-
termined by a Kyte-Doolittle analysis (Fig. 4) and could be
part of transmembrane domains which would normally be
antigenically conserved and embedded in the meningococ-
cal OM. More information about the physico-chemical
properties and the mechanism which control the expres-
sion of the proteins is needed to clearly associate the NspA
protein with the Opa proteins or to any other known men-
ingococcal surface protein.
Even if the biological function of the NspA protein is
not known at the moment, it is possible to determine using
mAb Me-1 whether this protein can induce an immune re-
sponse that can protect against meningococcal infection.
Mab Me-1 was shown to be bactericidal against four men-
ingococcal strains, one serogroup A, two serogroup B, and
one serogroup C, indicating that the observed bactericidal
activity is not restricted to one particular strain. It has been
well documented that serum bactericidal activity is the ma-
jor defense mechanism against N. meningitidis and that pro-
tection against invasion by the bacteria correlates with the
presence in human sera of anti-meningococcal antibodies
(20, 21). Conclusive evidence for the importance of bacte-
ricidal antibodies came from observations that individuals
with intact opsonophagocytic capacity (61), but with defi-
ciencies in one of the terminal complement components,
have enhanced risk of contracting meningococcal infec-
tions (62). To evaluate whether the observed bactericidal
activity of mAb Me-1 is not limited to a particular group of
strains, we are presently evaluating its activity against a
larger panel of serologically distinct meningococcal strains
in the presence of human complement. Additional infor-
mation about the localization of the NspA protein at the
surface of the meningococcal cells can also be deduced
from the bactericidal activity of mAb Me-1. Already, anal-
ysis of the migration profiles of meningococcal OM prepa-
rations have shown that the NspA protein is present in
these preparations (Fig. 1). The bactericidal assay results in-
dicate that the epitope recognized by mAb Me-1 is ex-
posed at the surface of intact meningococcal cells where it
is accessible to the antibodies. We are presently using a ra-
dioimmunobinding assay (56) and immunoelectron mi-
croscopy to further study the exposure of the NspA protein
at the surface of intact meningococcal cells and its accessi-
bility to specific antibodies. It is important to note that un-
like the common occurrence for OM proteins to have their
highly conserved regions embedded in the membrane
while their variable regions are surface exposed (63, 64),
the epitope on the NspA recognized by mAb Me-1 is ac-
cessible at the surface of intact bacteria. Furthermore, mAbs
can be used with different animal models of infection to
demonstrate the protective potential of a particular bacterial
antigen. Using this approach, mAbs directed against PorA
(25–27), PorB (25, 27, 28), Opc (27, 65), and LPS (27, 66)
were shown to passively protect against meningococcal ex-
perimental infection. The injection of the bactericidal mAb
Me-1 considerably improved the survival rate of the mice
against a deadly infection with the homologous meningo-
coccal strain 608B (Table 1). The combined results ob-
tained using the bactericidal assay and the passive protec-
tion clearly demonstrated that antibodies that are specific
for the NspA protein can efficiently protect against an ex-
perimental meningococcal infection. A new set of experi-
ments will have to be conducted in order to determine the
extend of protection conferred by mAb Me-1 when other
serologically distinct strains are used to challenge the mice.
There are several advantages in favor of recombinant
proteins for vaccine development: production of large
amount of protein, lack of contaminating undesirable ma-
terial, and the possibility to genetically modify the protein
to increase its immunogenicity or to reduce its toxicity. For
all these reasons we decided to use recombinant NspA pro-
tein instead of the native protein to clearly establish the
protective potential of this meningococcal minor surface
antigen. It is important to ascertain that the configuration
of the recombinant protein is close enough to the native
protein to generate functionally active antibodies. Indeed,
Idänpään-Heikkilä et al. (67) reported the production of
recombinant PorA protein in Bacillus subtilis as inclusion
bodies. They observed that the native-like epitopes neces-
sary to generate bactericidal and protective antibodies were
present only when the recombinant PorA protein was al-
lowed to refold in the presence of LPS or when it was in-
corporated into liposome. In our case, analysis of migration
profiles by SDS-PAGE of different antigenic preparations
extracted from E. coli strain BL21(DE3) transformed with
the plasmid pN2202 indicated that the recombinant NspA
protein is found in the OM as well as secreted in the cul-
ture supernatant (Fig. 3). Since there was no extensive sol-
ubilization and extraction steps necessary, we decided to
purify the recombinant NspA protein from the culture su-
pernatant by affinity chromatography. We hypothesized
that the recombinant NspA protein, which was secreted in
the culture supernatant through the bacterial OM, would
be correctly folded and would generate functionally active
antibodies. Data obtained from the protection experiments
and the subsequent analysis of the immune sera confirmed
that the recombinant protein shared enough immunologi-
cal characteristics with the native protein to induce such
antibodies. Indeed, 80% of the mice immunized with the1181 Martin et al.
recombinant NspA protein survived a deadly meningococ-
cal challenge (Table 2). This result clearly linked the ob-
served protection to the development of a specific immune
response. Analysis of in vitro bactericidal results also indi-
cated that cross-reactive bactericidal antibodies were present in
the sera obtained from all the mice who survived the bacte-
rial challenge.
In this report, we have presented results demonstrating
that the recombinant NspA protein can induce an immune
response that can protect against a lethal meningococcal in-
fection. We also presented data indicating that this protein
is present in the OM of all meningococcal strains where it
is accessible to the antibodies at the surface of living cells.
For all these reasons we believe that this protein possesses
all the important characteristics to be considered as a poten-
tial vaccine candidate. We are presently constructing men-
ingococcal mutant strains in order to study the function of
the NspA protein and to determine its possible role in the
meningococcal pathogenesis.
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